Table 1. Patient characteristics.

Variables/categories		S-1/cisplatin arm				Paclitaxel/cisplatin arm
		Cohort 1 (n = 41)		Cohort 2 (n = 23)		Cohort 1 (n = 42)		Cohort 2 (n = 23)
		No.	%	No.	%	No.	%	No.	%
Age (years)	Median (range)	65 (32–79)*		66 (41–79)*		66 (43–80)*		65 (44–76)*
Gender	Male	26	63	15	65	32	76	19	83
	Female	15	37	8	35	10	24	4	17
Performance status	0	41	100	23	100	40	95	23	100
	1	0	0	0	0	2	5	0	0
Macroscopic type	Non-scirrhous	30	73	14	61	27	64	14	61
	Type 4/giant type 3	11	27	9	39	15	36	9	39
Histological type	Differentiated	17	41	7	30	19	45	11	48
	Undifferentiated	24	59	16	70	23	55	12	52
Clinical T	T2	0	0	0	0	1	2	0	0
	T3	2	5	1	4	4	10	1	4
	T4a	36	88	20	87	32	76	21	91
	T4b	3	7	2	9	5	12	1	4
Clinical N	N0	5	12	4	17	7	17	5	22
	N1	19	46	11	48	16	38	8	35
	N2	17	41	8	35	18	43	9	39
	N3	0	0	0	0	1	2	1	4
Clinical M	Negative	35	85	21	91	34	81	21	91
	Positive	6	15	2	9	8	19	2	9
Site of M	CY1** and P0***	6	100	2	100	7	88	2	100
	Para-aortic nodes	0	0	0	0	1	12	0	0

^*Expressed as median (range), ^**CY1; positive for peritoneal lavage cytology, ^***P0; negative for peritoneal dissemination.